Sigilon Therapeutics, Inc. Quarterly Debt-to-equity in % from Q3 2021 to Q2 2023

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Sigilon Therapeutics, Inc. quarterly Debt-to-equity history and growth rate from Q3 2021 to Q2 2023.
  • Sigilon Therapeutics, Inc. Debt-to-equity for the quarter ending June 30, 2023 was 118 %, a 32.4% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q2 2023 118 +28.8 +32.4% Jun 30, 2023
Q1 2023 117 +37.7 +47.6% Mar 31, 2023
Q4 2022 108 +37.9 +54.2% Dec 31, 2022
Q3 2022 98.6 +36.3 +58.2% Sep 30, 2022
Q2 2022 88.9 Jun 30, 2022
Q1 2022 79.3 Mar 31, 2022
Q4 2021 69.9 Dec 31, 2021
Q3 2021 62.3 Sep 30, 2021
* An asterisk sign (*) next to the value indicates that the value is likely invalid.